Article
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Science (New York, N.Y.) - 28 Jul 2017
Le Dung T, Durham Jennifer N, Smith Kellie N, Wang Hao, Bartlett Bjarne R, Aulakh Laveet K, Lu Steve, Kemberling Holly, Wilt Cara, Luber Brandon S, Wong Fay, Azad Nilofer S, Rucki Agnieszka A, Laheru Dan, Donehower Ross, Zaheer Atif, Fisher George A, Crocenzi Todd S, Lee James J, Greten Tim F, Duffy Austin G, Ciombor Kristen K, Eyring Aleksandra D, Lam Bao H, Joe Andrew, Kang S Peter, Holdhoff Matthias, Danilova Ludmila, Cope Leslie, Meyer Christian, Zhou Shibin, Goldberg Richard M, Armstrong Deborah K, Bever Katherine M, Fader Amanda N, Taube Janis, Housseau Franck, Spetzler David, Xiao Nianqing, Pardoll Drew M, Papadopoulos Nickolas, Kinzler Kenneth W, Eshleman James R, Vogelstein Bert, Anders Robert A, Diaz Luis A
Abstract excerpt
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced...
Topics
Join the communities discussing this publication.